Brand Name | Status | Last Update |
---|---|---|
kerendia | New Drug Application | 2022-09-01 |
Expiration | Code | ||
---|---|---|---|
FINERENONE, KERENDIA, BAYER HLTHCARE | |||
2026-07-09 | NCE | ||
2025-09-01 | M-279 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 7 | 6 | 1 | 8 | 23 |
Chronic renal insufficiency | D051436 | — | N18 | 1 | 5 | 5 | 1 | 8 | 20 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 6 | 2 | 1 | 8 | 17 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 5 | 3 | 1 | 4 | 13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart failure | D006333 | EFO_0003144 | I50 | 3 | 3 | 2 | — | — | 8 |
Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | 2 | 2 | — | — | 5 |
Proteinuria | D011507 | — | R80 | — | — | 2 | — | — | 2 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Left ventricular dysfunction | D018487 | — | — | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Retinal diseases | D012164 | — | H35.9 | — | — | — | — | 2 | 2 |
Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | — | 2 | 2 |
Drug common name | Finerenone |
INN | finerenone |
Description | Finerenone, sold under the brand name Kerendia, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA). It is taken orally (swallowed by mouth).
|
Classification | Small molecule |
Drug class | aldosterone antagonists (spironolactone type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2 |
PDB | — |
CAS-ID | 1050477-31-0 |
RxCUI | — |
ChEMBL ID | CHEMBL2181927 |
ChEBI ID | — |
PubChem CID | 60150535 |
DrugBank | DB16165 |
UNII ID | DE2O63YV8R (ChemIDplus, GSRS) |